Browse by Series:

OncLive News Network On Location: ESMO 2019 Day 3

Gina Columbus
Published: Monday, Sep 30, 2019



Today-

We are on site at the Fira Gran Via in Barcelona, Spain, at the 2019 ESMO Congress!

We’ll be recapping some of the top news presented each day during the meeting—and soon we’ll speak with both Drs Hope Rugo and Joyce O’Shaughnessy on the biggest breast cancer data, Dr Mansoor Mirza on top abstracts in ovarian cancer, Dr Tanios Bekaii-Saab on some exciting gastrointestinal cancer research, and Dr Brad McGregor on some pivotal prostate cancer trials.

Welcome to OncLive News Network! I’m Gina Columbus.

Two CDK4/6 inhibitors demonstrated an improvement in overall survival when added to fulvestrant in patients with advanced hormone receptor–positive, HER2-negative breast cancer.

In the MONARCH 2 trial, the addition of abemaciclib to fulvestrant led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in this population of patients who progressed on prior endocrine therapy.

At a median follow-up of 47.7 months, the median OS with the combination of abemaciclib and fulvestrant was 46.7 months compared with 37.3 months for placebo/fulvestrant. The OS benefit was consistent across subgroups, including in patients with poor prognostic factors.

Additionally, results of the MONALEESA-3 study showcased an approximate 28% reduction in the risk of death with ribociclib and fulvestrant versus fulvestrant alone. The median OS was not reached in the ribociclib arm versus 40.0 months with placebo at a median follow-up of 39.4 months.

In patients with pretreated HER2-positive breast cancer, a numerical improvement in overall survival was seen with atezolizumab plus ado-trastuzumab emtansine versus T-DM1 alone in a second planned OS analysis of the phase II KATE2 trial.

The data suggest an OS benefit with atezolizumab plus T-DM1 in patients with PD-L1 expression in immune cells.

Trilaciclib combined with chemotherapy unexpectedly improved overall survival by more than 60% in metastatic triple-negative breast cancer, despite failing to meet a safety-related primary endpoint in a randomized phase II study.

The addition of trilaciclib to gemcitabine/carboplatin did not reduce the frequency and duration of severe neutropenia versus chemotherapy alone, nor did it improve progression-free survival and objective response rate.

The phase III KEYNOTE-522 trial demonstrated that neoadjuvant pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points versus chemotherapy alone for patients with early triple-negative breast cancer.

That’s all for today.

Thank you for watching OncLive News Network: On Location. Signing off from Barcelona, Spain, I’m Gina Columbus.
SELECTED
LANGUAGE
Slider Left
Slider Right


Today-

We are on site at the Fira Gran Via in Barcelona, Spain, at the 2019 ESMO Congress!

We’ll be recapping some of the top news presented each day during the meeting—and soon we’ll speak with both Drs Hope Rugo and Joyce O’Shaughnessy on the biggest breast cancer data, Dr Mansoor Mirza on top abstracts in ovarian cancer, Dr Tanios Bekaii-Saab on some exciting gastrointestinal cancer research, and Dr Brad McGregor on some pivotal prostate cancer trials.

Welcome to OncLive News Network! I’m Gina Columbus.

Two CDK4/6 inhibitors demonstrated an improvement in overall survival when added to fulvestrant in patients with advanced hormone receptor–positive, HER2-negative breast cancer.

In the MONARCH 2 trial, the addition of abemaciclib to fulvestrant led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in this population of patients who progressed on prior endocrine therapy.

At a median follow-up of 47.7 months, the median OS with the combination of abemaciclib and fulvestrant was 46.7 months compared with 37.3 months for placebo/fulvestrant. The OS benefit was consistent across subgroups, including in patients with poor prognostic factors.

Additionally, results of the MONALEESA-3 study showcased an approximate 28% reduction in the risk of death with ribociclib and fulvestrant versus fulvestrant alone. The median OS was not reached in the ribociclib arm versus 40.0 months with placebo at a median follow-up of 39.4 months.

In patients with pretreated HER2-positive breast cancer, a numerical improvement in overall survival was seen with atezolizumab plus ado-trastuzumab emtansine versus T-DM1 alone in a second planned OS analysis of the phase II KATE2 trial.

The data suggest an OS benefit with atezolizumab plus T-DM1 in patients with PD-L1 expression in immune cells.

Trilaciclib combined with chemotherapy unexpectedly improved overall survival by more than 60% in metastatic triple-negative breast cancer, despite failing to meet a safety-related primary endpoint in a randomized phase II study.

The addition of trilaciclib to gemcitabine/carboplatin did not reduce the frequency and duration of severe neutropenia versus chemotherapy alone, nor did it improve progression-free survival and objective response rate.

The phase III KEYNOTE-522 trial demonstrated that neoadjuvant pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points versus chemotherapy alone for patients with early triple-negative breast cancer.

That’s all for today.

Thank you for watching OncLive News Network: On Location. Signing off from Barcelona, Spain, I’m Gina Columbus.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x